Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The antibiotic subscription model: fostering innovation or repackaging old drugs?
R. E. Glover, Andrew C. Singer, Adam P. Roberts, et al.
The Lancet Microbe (2022) Vol. 4, Iss. 1, pp. e2-e3
Open Access | Times Cited: 13

Showing 13 citing articles:

Antibiotics in the clinical pipeline as of December 2022
Mark S. Butler, Ian R. Henderson, Robert J. Capon, et al.
The Journal of Antibiotics (2023) Vol. 76, Iss. 8, pp. 431-473
Open Access | Times Cited: 129
Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance
Ramanan Laxminarayan, Isabella Impalli, Radha Rangarajan, et al.
The Lancet (2024) Vol. 403, Iss. 10443, pp. 2534-2550
Closed Access | Times Cited: 41
A Review of Antibacterial Candidates with New Modes of Action
Mark S. Butler, Waldemar Vollmer, Emily C. A. Goodall, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 10, pp. 3440-3474
Open Access | Times Cited: 16
AHL-Based Quorum Sensing Regulates the Biosynthesis of a Variety of Bioactive Molecules in Bacteria
Mélanie Gonzales, Pauline Jacquet, Floriane Gaucher, et al.
Journal of Natural Products (2024) Vol. 87, Iss. 4, pp. 1268-1284
Closed Access | Times Cited: 5
Non-Canonical Aspects of Antibiotics and Antibiotic Resistance
Carlos F. Amábile-Cuevas, Sofia Lund-Zaina
Antibiotics (2024) Vol. 13, Iss. 6, pp. 565-565
Open Access | Times Cited: 4
Innovative perspectives on the discovery of small molecule antibiotics
Silvia T. Cardona, A. S. M. Zisanur Rahman, Julieta Novomisky Nechcoff
npj Antimicrobials and Resistance (2025) Vol. 3, Iss. 1
Open Access
Nanocomposite orthopaedic bone cement combining long-acting dual antimicrobial drugs
Lirong Yang, Abdulla A. Yergeshov, Yazan Al Thaher, et al.
Biomaterials Advances (2023) Vol. 153, pp. 213538-213538
Open Access | Times Cited: 10
Global Pull Incentives for Better Antibacterials: The UK Leads the Way
Kevin Outterson, John Rex
Applied Health Economics and Health Policy (2023) Vol. 21, Iss. 3, pp. 361-364
Open Access | Times Cited: 8
Why is the UK subscription model for antibiotics considered successful?
R. E. Glover, Andrew C. Singer, Adam P. Roberts, et al.
The Lancet Microbe (2023) Vol. 4, Iss. 11, pp. e852-e853
Open Access | Times Cited: 6
The Antibiotics Dilemma: Reducing use while rewarding investment
G. Kent Fellows, Alexia Hill
SSRN Electronic Journal (2024)
Closed Access | Times Cited: 1
Quantifying the Economic and Clinical Value of Reducing Antimicrobial Resistance in Gram-negative Pathogens Causing Hospital-Acquired Infections in Australia
Jason Gordon, Amer Al-Taie, Ryan Miller, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 7, pp. 1875-1889
Open Access | Times Cited: 3
Exploring the views of infection consultants in England on a novel delinked funding model for antimicrobials: the SMASH study
Ioannis Baltas, Mark Gilchrist, Eirini Koutoumanou, et al.
JAC-Antimicrobial Resistance (2023) Vol. 5, Iss. 4
Open Access | Times Cited: 3
Antibiotic shortages in Europe: Another question of prices?
Livio Garattini, Bruno Finazzi, Antonino Mazzone
European Journal of Internal Medicine (2024) Vol. 125, pp. 142-144
Closed Access
Page 1

Scroll to top